UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

 

Date of Report: May 3, 2018

(Date of earliest event reported)

 

 

TENET HEALTHCARE CORPORATION

(Exact name of Registrant as specified in its charter)

 

 

 

Nevada   1-7293   95-2557091
(State of Incorporation)  

(Commission

File Number)

 

(IRS Employer

Identification Number)

1445 Ross Avenue, Suite 1400

Dallas, Texas 75202

(Address of principal executive offices, including zip code)

(469) 893-2200

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging Growth Company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 


Item 5.07. Submission of Matters to a Vote of Security Holders.

(a)    The 2018 annual meeting of shareholders of Tenet Healthcare Corporation (the “Company”) was held on May 3, 2018.

(b)    The Company’s shareholders (1) elected all eight of the nominees for director, (2) approved, on an advisory basis, the Company’s executive compensation, (3) ratified the selection of Deloitte & Touche LLP as the Company’s independent registered public accountants for the year ending December 31, 2018, and (4) did not approve a shareholder proposal regarding an independent board chairman.

The final results of voting on each of the matters submitted to a vote are set forth below. Abstentions and broker non-votes were counted for purposes of determining whether a quorum was present but were not counted as votes cast on any matter.

1.    Election of directors:

 

     FOR      AGAINST      ABSTAIN      BROKER
NON-VOTES
 

Ronald A. Rittenmeyer

     79,137,925        2,622,326        61,100        10,600,865  

J. Robert Kerrey

     80,463,154        1,311,498        46,699        10,600,865  

James L. Bierman

     81,468,016        304,871        48,464        10,600,865  

Richard W. Fisher

     80,414,501        1,360,858        45,992        10,600,865  

Brenda J. Gaines

     79,727,501        2,047,489        46,361        10,600,865  

Edward A. Kangas

     79,614,623        2,151,745        54,983        10,600,865  

Richard J. Mark

     81,476,437        297,552        47,362        10,600,865  

Tammy Romo

     80,338,235        1,431,884        51,232        10,600,865  

2.    Approval, on an advisory basis, of the Company’s executive compensation:

 

FOR   AGAINST   ABSTAIN   BROKER
NON-VOTES

79,558,330

  2,211,545   51,476   10,600,865

3.    Ratification of the selection of Deloitte & Touche LLP as the Company’s independent registered public accountants for the year ending December 31, 2018:

 

FOR   AGAINST   ABSTAIN   BROKER
NON-VOTES

90,405,212

  1,934,869   82,135   —  

4.    Shareholder proposal to urge the Board to adopt a policy that the chairman of the Board be an independent director:

 

FOR   AGAINST   ABSTAIN   BROKER
NON-VOTES

15,652,004

  65,897,956   271,391   10,600,865


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

TENET HEALTHCARE CORPORATION
By:  

/s/ Paul A. Castanon

  Paul A. Castanon
  Vice President, Deputy General Counsel and Corporate Secretary

Date: May 7, 2018